President Obama faces a messy political fight over the federal court ruling striking down his new, looser policy letting federal grant money pay for stem cell research involving “destroyed” embryos.
Why the “Mad Money” host has faith in this pharmacy-benefit manager, even though the market may not.
Medical tourism, family travel and international migration have combined to import a potent new form of antibiotic resistance halfway around the planet—and the physician-researchers who have tracked its rapid spread say it is already on the verge of becoming untreatable.
Baby Boomers want to live longer and to live better. The convergence of Boomer expectations and technology is forging a disruptive force that will improve life tomorrow for everyone.
Two reports published Friday offer novel approaches to the age-old dream of regenerating the body from its own cells.
Unsafe drinking water is the world’s largest cause of disease and death. The United Nations Development Program has stated that every $1 invested in water and sanitation produces $9 in healthcare cost reduction and economic development.
Health care spending both contributes to our current economic difficulties and provides us with a potential opportunity to help solve them. It is a great burden on companies, while at the same time it is helping create jobs.
Here's why you should keep a close eye on these six stocks.
The drug maker reported Friday a quarterly operating profit that topped Wall Street expectations and issued full-year guidance in line with current forecasts, but sales were slightly below the consensus estimate.
If Sanofi moves ahead with an unsolicited offer for Genzyme, there will be plenty of biotech investors and investment bankers shaking their heads in wonderment, particularly if it is at a price well above Genzyme’s current level.
The very large French pharmaceutical company made an informal acquisition approach to Genzyme. That approach was essentially rebuffed and not met with any significant talks, according to people familiar with the matter. However, especially in recent days, talks have been heating up.
Counterfeiters have created an international, multi-billion-dollar industry by making cheap imitations of designer goods and selling them for a fraction of the price.
Today's six stocks worth watching.
The last thing anyone checking into a hospital should have to worry about is getting sicker while there. Yet, hospital-acquired infections are the most common complication of hospital care, claiming about 99,000 lives and costing the U.S. healthcare system about $30 billion each year.
Today's six stocks worth watching.
Shares in AstraZeneca rose sharply in London Wednesday after the drug company won a U.S. court ruling to protect a patent for its blockbuster cholesterol drug, Crestor.
Diabetes has become a pandemic of monumental proportion. Not only has it threatened the lives of millions, but it also has added to the massive economic burden of chronic disease.
Amylin Pharmaceuticals , whose stock rose 20 percent over the last month, is encouraged by a recent study that its experimental drug Bydureon is well tolerated by patients suffering from Type 2 diabetes.
While most people living in the United States might think tuberculosis is a disease that no longer affects this country, in reality, between nine and 14 million Americans are infected with the bacteria that cause TB.
It doesn’t strike the kind of terror that cancer or Alzheimer’s disease do. But there’s a killer hiding in plain sight that might wreak even more devastation: diabetes.